
Global & Switzerland Cancer Therapeutics Market to 2031
Description
According to data from MonAM, a collaborative initiative between the Swiss Federal Office of Public Health (FOPH) and the Swiss Health Observatory (Obsan), Switzerland reported approximately 45,600 new cancer cases annually between 2018 and 2022, equating to roughly 377 cases per 100,000 people. The high incidence of cancer highlights the urgent need for effective treatment options in the country.
In 2018, Switzerland joined forces with Australia, Canada, and Singapore to launch the New Chemical Entities Work Sharing Initiative—a joint effort aimed at streamlining the evaluation and approval of new drugs. Among the first approvals under this initiative were apalutamide for prostate cancer, abemaciclib for breast cancer, and niraparib for cancers of the ovary, fallopian tube, or peritoneum.
Building on this momentum, Switzerland introduced a temporary drug approval pathway in 2019 for medications already authorized elsewhere. This regulatory mechanism enabled faster patient access to innovative therapies such as larotrectinib and cemiplimab, both used in the treatment of cutaneous squamous cell carcinoma.
The Swiss government continues to prioritize improvements in cancer care, with a focus on early detection and access to advanced therapies. Initiatives like the Swiss Cancer League’s Cancer Control Program play a crucial role in reducing the overall cancer burden by funding vital research and offering support services to patients and their families.
In 2018, Switzerland joined forces with Australia, Canada, and Singapore to launch the New Chemical Entities Work Sharing Initiative—a joint effort aimed at streamlining the evaluation and approval of new drugs. Among the first approvals under this initiative were apalutamide for prostate cancer, abemaciclib for breast cancer, and niraparib for cancers of the ovary, fallopian tube, or peritoneum.
Building on this momentum, Switzerland introduced a temporary drug approval pathway in 2019 for medications already authorized elsewhere. This regulatory mechanism enabled faster patient access to innovative therapies such as larotrectinib and cemiplimab, both used in the treatment of cutaneous squamous cell carcinoma.
The Swiss government continues to prioritize improvements in cancer care, with a focus on early detection and access to advanced therapies. Initiatives like the Swiss Cancer League’s Cancer Control Program play a crucial role in reducing the overall cancer burden by funding vital research and offering support services to patients and their families.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Switzerland Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Switzerland Cancer Therapeutics Market – Analysis
- 6.1 Switzerland Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Switzerland Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Switzerland Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Switzerland Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Switzerland Cancer Therapeutics Market Analysis – by Indications
- 8.1 Switzerland Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Switzerland Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Switzerland Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Switzerland Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Switzerland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Switzerland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Switzerland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Switzerland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Switzerland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Switzerland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Switzerland Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Switzerland Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Switzerland Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.